Sangon Biotech: difference between revisions
Diff·revision 23 → 24·12:07, 6 Apr 2025
Difference between revision 23 and revision 24 of Sangon Biotech. 9 lines changed; the page grew by 377 bytes.
| Revision 23 — 15:01, 29 Mar 2025 SecondarySrc_Seb (talk) add DOI 6,262 bytes +318 | Revision 24 — 12:07, 6 Apr 2025 ChainCustodyChad (talk) remove weasel wording 6,639 bytes +377 | ||
|---|---|---|---|
| 47 | | SARMs and raw materials | Bulk | Certificate, purity | | 47 | | SARMs and raw materials | Bulk | Certificate, purity | |
| 48 | 48 | ||
| + | 49 | The reagent and oligonucleotide lines place this organisation in a different category from most covered here. Its inclusion in this wiki's supplier articles reflects its peptide listings, not the whole of its business.{{r|selfpub}} | |
| + | 50 | ||
| 49 | == References == | 51 | == References == |
| 50 | {{reflist}} | 52 | {{reflist}} |
| ⋮ | ⋮ | ||
| 55 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 57 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 56 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 58 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |
| + | 59 | ||
| + | 60 | == See also == | |
| + | 61 | * [[Certificate of analysis]] | |
| + | 62 | * [[Third-party testing]] | |
| + | 63 | * [[Area percent purity]] | |
| + | 64 | * [[Peptide content]] | |
| + | 65 | * [[Research use only]] | |
| 57 | 66 | ||
| 58 | {{DEFAULTSORT:Sangon Biotech}} | 67 | {{DEFAULTSORT:Sangon Biotech}} |